The FDA has approved a new option for the long-term maintenance treatment of airflow obstruction in individuals with chronic obstructive pulmonary disease.
The US Food and Drug Administration recently approved the first single dose once-daily inhaler to be used as maintenance therapy for patients with chronic obstructive pulmonary disease.
The FDA has approved a drug already indicated for COPD treatment for the long-term, once-daily maintenance of asthma in individuals 12 years old and older.
